Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00435461 · ClinicalTrials.gov registry record · Phase 4

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

A Phase 4 study of Rhinitis, Allergic, Seasonal, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
1,000
Enrollment target
6
Study locations

NCT00435461 is a Phase 4 study of Rhinitis, Allergic, Seasonal that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,000 participants, above the 526-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (90% higher). The trial reports 6 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00435461, a Phase 4 study of Rhinitis, Allergic, Seasonal, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
1,000 participants
Enrollment target
6
Study locations

Study Summary

The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine

Interventions

  • DRUG Fluticasone furoate and fexofenadine

Study Locations (6)

Texas

  • GSK Investigational Site - Austin
  • GSK Investigational Site - Austin
  • GSK Investigational Site - Kerrville
  • GSK Investigational Site - New Braunfels
  • GSK Investigational Site - San Antonio
  • GSK Investigational Site - San Antonio

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2006-12-20
Est. Completion 2007-02-28
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT00435461

The ClinicalTrials.gov registry entry for NCT00435461 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 526-participant average among 3 other Rhinitis, Allergic, Seasonal trials with a reported enrollment target (90% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rhinitis, Allergic, Seasonal appearing as the primary indexed condition, and to 1 intervention - of which Fluticasone furoate and fexofenadine is the first listed.

NCT00435461 reports 6 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00435461 about?

NCT00435461 is a clinical study titled "Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine". The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine

What is the current status of trial NCT00435461?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,000 participants. The study started on 2006-12-20. Estimated completion is 2007-02-28.

What conditions does trial NCT00435461 study?

This clinical trial studies the following conditions: Rhinitis, Allergic, Seasonal.

What interventions are being tested in trial NCT00435461?

The interventions under investigation include: Fluticasone furoate and fexofenadine (DRUG).

Who is sponsoring clinical trial NCT00435461?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00435461 being conducted?

This trial has 6 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rhinitis, Allergic, Seasonal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.